Dr. Manasanch is an Assistant Professor at the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center. She graduated with an M.D. degree from the University of Barcelona in 2005 and received an M.H.Sc. in Clinical Research from Duke University in 2014. She pursued internal medicine and medical oncology training at the University of Massachusetts and National Institutes of Health, respectively and is board-certified in both specialties. During her fellowship training at the National Institutes of Health, Dr. Manasanch focused on the research and treatment of plasma cell dyscrasias. In 2014, she was awarded the M.D. Anderson Cancer Center Clinical Innovator Award to study predictors of outcome after anti-CD38 antibody therapy in intermediate and high-risk smoldering multiple myeloma. She received the International Myeloma Foundation 2015 Brian D. Novis Research Award to implement minimal residual disease testing in multiple myeloma. In 2016, she received the High Impact Clinical Research Support Program Award to support clinical research personnel funding. Currently, she leads the myeloma precursor disease program at MD Anderson with a focus in understanding early stages through new technology and applying immunotherapy to early treatment. A prospective observational clinical trial of MGUS and SMM is currently accruing participants to identify/validate prediction models for progression to multiple myeloma, understand the etiology and analyze new markers to target. Interventional trials with monoclonal antibodies in intermediate and high-risk SMM are currently ongoing at MD Anderson and led by Dr. Manasanch.